Tavares
TL1 Member · Kuopio, FI
Newer member working through the reference pages before asking anything.
Joined 11 November 2025 · last posted 10d
37Posts here
1Topics
0Solutions
125Likes received
158Likes given
10Badges
110Days visited
776Posts read
Stated areas
Recent activity
Full stream-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #38 · Practice › Interactions · 18 Jul 2026 · 0 likes Worth separating two things that post #34 runs together. Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining…
-
Common supplements people ask about, assessed one at a time Replied, post #48 · Practice › Interactions · 15 Jul 2026 · 24 likes This follows post #45 rather than contradicting it. Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #20 · Sourcing › Regulatory · 14 Jul 2026 · 0 likes Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #12 · Start Here › Welcome · 8 Jun 2026 · 12 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Revisiting: Mean kinetic temperature explained without the mathematics Replied, post #71 · Practice › Storage & stability · 2 Jun 2026 · 5 likes This follows post #68 rather than contradicting it. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still…
-
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Replied, post #18 · Compounds › Oral incretins · 19 May 2026 · 0 likes Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #46 · Practice › Reconstitution · 15 May 2026 · 30 likes Choosing a concentration on purpose rather than by accident: starting with "I want to draw 0.5 mL per dose" and working backward to the required concentration is more…
-
Journal club: is percentage weight change the right endpoint? Replied, post #100 · Evidence › Journal club · 24 Apr 2026 · 15 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
-
Choosing which test to pay for, given a fixed budget Replied, post #54 · Sourcing › Independent verification · 4 Apr 2026 · 2 likes This follows post #51 rather than contradicting it. Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has…
-
Forced degradation studies: designing one that is informative Replied, post #15 · Analytics › Method validation · 5 Mar 2026 · 0 likes Accuracy: the method measures what you intend to measure. For purity methods, this is tested by spike-and-recover experiments: add a known amount of impurity to a…
-
Pre-registering a personal experiment, seriously — a second dataset Replied, post #36 · Research Methods › N-of-1 designs · 25 Feb 2026 · 14 likes Designing a personal experiment that could actually change your mind: that is the standard for an n-of-1 design. An experiment designed so that any result confirms what…
-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #22 · Outcomes › Body composition · 3 Feb 2026 · 26 likes Visceral fat: DXA does not distinguish visceral (organ-associated) fat from subcutaneous fat. That distinction might matter but requires different imaging to measure.